248 related articles for article (PubMed ID: 11604550)
1. Capecitabine: a novel agent for the treatment of solid tumors.
Johnston PG; Kaye S
Anticancer Drugs; 2001 Sep; 12(8):639-46. PubMed ID: 11604550
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine: effective oral fluoropyrimidine chemotherapy.
McKendrick J; Coutsouvelis J
Expert Opin Pharmacother; 2005 Jun; 6(7):1231-9. PubMed ID: 15957975
[TBL] [Abstract][Full Text] [Related]
4. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Folprecht G; Köhne CH
Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
[TBL] [Abstract][Full Text] [Related]
5. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
[TBL] [Abstract][Full Text] [Related]
6. Practical considerations in the use of oral fluoropyrimidines.
Hoff PM
Semin Oncol; 2003 Jun; 30(3 Suppl 6):88-92. PubMed ID: 12802799
[TBL] [Abstract][Full Text] [Related]
7. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Malet-Martino M; Martino R
Oncologist; 2002; 7(4):288-323. PubMed ID: 12185293
[TBL] [Abstract][Full Text] [Related]
8. Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?
Seidman AD; O'Shaughnessy J; Misset JL
Oncologist; 2002; 7 Suppl 6():20-8. PubMed ID: 12454316
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
Wagstaff AJ; Ibbotson T; Goa KL
Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
11. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Van Cutsem E; Verslype C; Tejpar S
Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
[TBL] [Abstract][Full Text] [Related]
12. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Cunningham D; Coleman R
Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
[TBL] [Abstract][Full Text] [Related]
13. Rational development of capecitabine.
Venturini M
Eur J Cancer; 2002 Feb; 38 Suppl 2():3-9. PubMed ID: 11841929
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine: indications and future perspectives in the treatment of metastatic colorectal and breast cancer.
Cassata A; Procoplo G; Alù M; Ferrari L; Ferrario E; Beretta E; Longarini R; Busto G; De Candis D; Bajetta E
Tumori; 2001; 87(6):364-71. PubMed ID: 11989587
[TBL] [Abstract][Full Text] [Related]
16. The evolution of fluoropyrimidine therapy: from intravenous to oral.
Hoff PM; Cassidy J; Schmoll HJ
Oncologist; 2001; 6 Suppl 4():3-11. PubMed ID: 11585968
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of capecitabine in breast cancer.
Daniele G; Gallo M; Piccirillo MC; Giordano P; D'Alessio A; Del Giudice A; La Porta ML; Perrone F; Normanno N; De Luca A
Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):225-35. PubMed ID: 23301520
[TBL] [Abstract][Full Text] [Related]
18. The rational development of capecitabine from the laboratory to the clinic.
Pentheroudakis G; Twelves C
Anticancer Res; 2002; 22(6B):3589-96. PubMed ID: 12552961
[TBL] [Abstract][Full Text] [Related]
19. Potential of Xeloda in colorectal cancer and other solid tumors.
Cassidy J
Oncology; 1999 Jul; 57 Suppl 1():27-32. PubMed ID: 10436414
[TBL] [Abstract][Full Text] [Related]
20. Integrating oxaliplatin into the management of colorectal cancer.
Schmoll HJ; Cassidy J
Oncologist; 2001; 6 Suppl 4():24-8. PubMed ID: 11585971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
